Peroxisome Proliferator-Activated Receptors: “Key” Regulators of Neuroinflammation after  Traumatic Brain Injury by Stahel, Philip F. et al.
Hindawi Publishing Corporation
PPAR Research




“Key” Regulators of Neuroinﬂammation after
Traumatic Brain Injury
Philip F. Stahel,1 Wade R. Smith,1 Jay Bruchis,1 and Craig H. Rabb2
1Department of Orthopedic Surgery, Denver Health Medical Center, School of Medicine, University of Colorado,
777 Bannock Street, Denver, CO 80204, USA
2Division of Neurosurgery, Department of Surgery, Denver Health Medical Center, School of Medicine, University of Colorado,
777 Bannock Street, Denver, CO 80204, USA
Correspondence should be addressed to Philip F. Stahel, philip.stahel@dhha.org
Received 24 December 2007; Accepted 29 January 2008
Recommended by Paul Drew
Traumatic brain injury is characterized by neuroinﬂammatory pathological sequelae which contribute to brain edema and de-
layed neuronal cell death. Until present, no speciﬁc pharmacological compound has been found, which attenuates these patho-
physiological events and improves the outcome after head injury. Recent experimental studies suggest that targeting peroxisome
proliferator-activated receptors (PPARs) may represent a new anti-inﬂammatory therapeutic concept for traumatic brain injury.
PPARs are “key” transcription factors which inhibit NFκB activity and downstream transcription products, such as proinﬂam-
matory and proapoptotic cytokines. The present review outlines our current understanding of PPAR-mediated neuroprotective
mechanisms in the injured brain and discusses potential future anti-inﬂammatory strategies for head-injured patients, with an
emphasis on the putative beneﬁcial combination therapy of synthetic cannabinoids (e.g., dexanabinol) with PPARα agonists (e.g.,
fenoﬁbrate).
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1. INTRODUCTION
Research eﬀorts in recent years have provided increasing ev-
idence that the intracerebral inﬂammatory response is in
large part responsible for the devastating neuropathological
sequelae and poor outcome of traumatic brain injury [1–
3]. The extent of brain damage is determined by primary
and secondary injury patterns. While the primary injury re-
sults from mechanical forces applied to the skull and brain
at the time of impact, secondary brain injury occurs as a
delayed consequence of trauma [4–7]. Secondary brain in-
juries are mediated by endogenous pathophysiological pro-
cesses which lead to an overwhelming neuroinﬂammation in
the injured brain [6, 8–10] .T h em a i nr i s kf a c t o r sf o rd e v e l -
oping secondary brain injuries are hypoxemia and systemic
hypotension which occur frequently in the trauma patient
[11, 12]. These conditions contribute to the ischemic brain
damage and perpetuate the intracerebral inﬂammatory re-
action through ischemia/reperfusion-mediated mechanisms
[13]. Peroxisome proliferator-activated receptors (PPARs)
are ligand-activated transcription factors of the nuclear
receptor superfamily which have recently been shown to ex-
ert anti-inﬂammatory properties in acute neurological dis-
orders. These include cerebrovascular stroke, intracerebral
hemorrhage, spinal cord injury, and traumatic brain injury
[14–21]. The present paper provides an overview on the so
far known anti-inﬂammatory properties of PPARs in brain
injury and discusses potential pharmacological properties of
PPAR agonists as future neuroprotective agents.
2. BIOLOGICAL FUNCTIONS OF PPARs
PPARs are nuclear membrane-associated transcription fac-
tors belonging to the nuclear receptor family [22]. Three iso-
types with a diﬀerential tissue distribution have been de-
scribed: PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ
(NR1C3) [23, 24]. While PPARβ/δ has an ubiquitous ex-










Figure 1: Mechanism of gene transcription through ligand binding
on peroxisome proliferator-activated receptors (PPARs). In presence
of coactivating stimuli, PPARs heterodimerize with retinoid X re-
ceptors (RXR) to form active transcription factors. The DNA bind-
ing domain on PPAR-RXR heterodimers induces the transcription
of target genes by binding to peroxisome proliferator-response ele-
ments (PPRE’s) which consist of DNA-speciﬁc sequences.
with high fatty acid catabolism, such as adipose tissue, liver,
kidney, and skeletal muscle [25]. Mechanistically, PPARs
are activated by heterodimerization with the retinoid-X re-
ceptor (RXR) into biologically active transcription factors.
PPAR-RXR heterodimers induce the transcription of candi-
date genes by binding to so-called peroxisome proliferator-
response elements (PPRE’s) consisting of DNA-speciﬁc se-
quences (see Figure 1).
PPARs exert a wide variety of physiological functions
[24, 26]. They play a central role in the regulation of lipid
and lipoprotein metabolism and glucose homeostasis, and
have been shown to mediate cellular proliferation and pro-
grammed cell death (apoptosis) [27–31]. PPARs have fur-
thermore been involved in bone metabolism and in patholo-
gies of the cardiovascular system and the lung [32–35].
PPARα has been attributed important immunological func-
tions due to its expression on monocytes/macrophages, T
cells, and vascular endothelial cells. PPARγ appears to play
a crucial role in the regulation of proliferation and diﬀer-
entiation of various cell types. While the biological role of
PPARβ/δ has not been deﬁned in detail, recent data imply
anantiapoptotic andanti-inﬂammatoryeﬀectaftertissuein-
jury, both in vitro and in vivo [29].
From an immunological viewpoint, PPARs have been
identiﬁed as important regulators of inﬂammatory gene ex-
pression [36–40]. PPARs have also been shown to attenu-
ate adaptive immune responses by inhibiting helper T cell
functions and by mediating apoptosis of B cells [41, 42].
PPARs are activated by naturally ocurring fatty acid deriva-
tives, eicosanoides, and by synthetic pharmacological agents,
suchasﬁbrates(PPARα)andglitazones(PPARγ)[18,22,43].
PPAR ligands have been shown to exert anti-inﬂammatory
activities in various cell types by inhibiting the gene expres-
sion for proinﬂammatory cytokines, metalloproteinases, and
hepatic acute-phase proteins.
3. PPARs: “KEY” REGULATORS OF
NEUROINFLAMMATION
Mechanistically, the activation of PPARα has been shown to
inhibitproinﬂammatorygenetranscriptionbyrepressingthe
central inﬂammatory transcription factor, nuclear factor-κB
(NF-κB) [43–45]. Along with suppression of NF-κB, PPARα
acts by inhibition of signal transduction through activator
protein-1(AP-1)signaling[43].Itappearsthattheinhibitory
eﬀect of PPARα on these crucial inﬂammatory transcription
factors creates a negative feedback loop for controlling acute
posttraumatic inﬂammation [44–46]. First in vivo data on
the involvement of PPARs in the regulation of inﬂamma-
tion were reported from studies in PPARα knockout mice
[47]. Cuzzocrea et al. showed that the targeted deletion of
the PPARα gene leads to a signiﬁcantly increased inﬂamma-
tory response in diﬀerent experimental models of acute in-
ﬂammation outside the central nervous system (CNS) [47].
Within the CNS, the constitutive expression of PPARs has
been described for some time [48, 49]. Interestingly, PPAR
gene expression was detected not only on vascular endothe-
lialcellsinthebrainandspinalcord,butalsoonresidentcells
in the CNS, such as neurons and glial cells [49].
4. ROLE OF PPARs IN CNS INJURY
In recent years, experimental studies in models of cerebral
ischemia/reperfusion injury, ischemic stroke, intracerebral
hemorrhage, and spinal cord injury have revealed a cru-
cial role of PPARs in attenuating neuroinﬂammation and
neuronal cell death in the injured CNS (see Table 1)[ 14–
16, 19, 20, 50–52]. PPARα gene-deﬁcient mice (PPARα−/−)
were shown to have a signiﬁcantly worsened neurological
outcome, associated with an increased neuroinﬂammatory
response to experimental spinal cord injury, as compared to
wild-type littermates [16]. The postulated neuroprotective
eﬀects of natural PPARα ligands include the attenuation of
polymorphonuclear leukocyte (PMNL) recruitment and as-
sociated neurotoxicity, as determined by a signiﬁcantly re-
duced expression of myeloperoxidase in the injured spinal
cord of PPARα − /− mice [16]. In addition, tumor necro-
sis factor (TNF), a “key” mediator of neuroinﬂammation
and neurotoxicity, was shown to be upregulated and asso-
ciated with neuronal apoptosis in the injured spinal cord of
PPARα−/−mice[16].Intraumaticbraininjury,experimen-
tal studies in the past decade have shown that TNF is upreg-
ulated in the intracranial compartment within a few hours
after trauma, and contributes to secondary neuronal injury
[53–55]. The deleterious neurotoxic eﬀects were shown to be
abrogated by pharmacological inhibition of TNF [56]. Since
PPARs inhibit proinﬂammatory gene transcription by atten-
uating NF-κB signaling [43–45], the potent PPAR-mediated
neuroprotective eﬀects may be dependent on inhibition
of NF-κB-dependent proinﬂammatory cytokines released in
the injured brain, such as TNF, interleukin (IL)-1, IL-8, IL-
12, and IL-18 [57–61]. The central role of NF-κB signaling in
inﬂammation and oxidative stress explains why PPARs have
been considered possible targets for neuroprotection in in-Philip F. Stahel et al. 3
Table 1: Selected publications on the role of PPARs in CNS injury and inﬂammation.
Models of CNS injury and
neuroinﬂammation PPAR isotype Main ﬁndings Reference no.
Diﬀerent models of CNS injury PPARγ Review on the mechanisms of neuroprotection by PPARγ
agonists
Kapadia et al. [20]
Diﬀerent models of CNS injury PPARα,P P A R γ Review on pharmacological neuroprotection by PPARs Bordet et al. [14]
Brain inﬂammation PPARγ Review on regulation of microglial activation by PPARγ
agonists
Bernardo and Minghetti [63]
Spinal cord injury All isotypes Review on the role of PPAR signal transduction in spinal
cord injury
Van Neerven and Mey [15]
Spinal cord injury PPARα
Experimental model of spinal cord injury in PPARα gene
knockout mice. Lack of PPARα leads to worse outcome
and increased neuroinﬂammation.
Genovese et al. [16]
Cerebral ischemia/reperfusion
injury PPARγ
The PPARγ agonists rosiglitazone and pioglitazone exert
neuroprotective eﬀects in a rat model of cerebral
ischemia/reperfusion injury by reducing
neuroinﬂammation and oxidative stress.
Collino et al. [50]
Intracerebral hemorrhage PPARγ
PPARγ expressed by microglia and macrophages promotes
the resolution of intracerebral hemorrhage and attenuates
the neuroinﬂammatory response.
Zhao et al. [19]
Traumatic brain injury PPARα
The PPARα agonist fenoﬁbrate reduces brain edema and
improves the neurological outcome after experimental
ﬂuid percussion brain injury in male Sprague-Dawley rats.
Besson et al. [21]
Traumatic brain injury PPARα
The PPARα agonist fenoﬁbrate promotes neurological
recovery by reducing inﬂammation and oxidative stress in
rat brains after experimental ﬂuid percussion brain injury.
Chen et al. [17]
Neuroinﬂammation All isotypes Review on the interaction between cannabinoids and
PPARs as inhibitors of neuroinﬂammation
Sun and Bennett [83]
ﬂammatory CNS diseases, including traumatic brain injury
[14, 20, 62, 63].
5. PHARMACOLOGY OF HEAD INJURY:
ARE PPAR-AGONISTS AND CANNABINOIDS
THE LONG SOUGHT “GOLDEN BULLET”?
A wide variety of natural and synthetic PPARγ agonists have
been described in recent years as regulators of microglial
activation and cerebral inﬂammation [63]. For example, the
thiazolinedione pioglitazone has been shown to reduce the
extent of neuroinﬂammation and the severity of disease in
experimental autoimmune encephalomyelitis (EAE), the an-
imalmodelformultiplesclerosis(MS)[64,65].Arecentcase
report described the impressive clinical improvement of a
patient with chronic progressive MS, after a 3-year period
of treatment with pioglitazone [66]. This unexpected clin-
ical recovery implies that PPARγ agonists may represent a
promising new strategy for attenuating neuroinﬂammation
in patients with CNS autoimmune diseases [62, 63, 67].
In cerebrovascular stroke, the combination therapy
of a PPARγ agonist (rosiglitazone) with an antiexcito-
toxic glutamate receptor antagonist (MK-801) led to an
improved neurological recovery in rats undergoing mid-
dle cerebral artery occlusion [18]. A study by another
group assessed the therapeutic eﬃcacy of two diﬀerent
PPARγ agonists, rosiglitazone and pioglitazone, in a rat
model of cerebral ischemia/reperfusion injury [50]. The au-
thors showed that the pretreatment with either compound
led to a signiﬁcant attenuation of inﬂammation and oxida-
tive stress in injured rat brains [50].
Pharmacological ligands to PPARα,s u c ha sf e n o ﬁ b r a t e ,
have also been shown to exert neuroprotective eﬀects in in-
ﬂammatory CNS conditions. Deplanque et al. demonstrated
asigniﬁcantneuroprotectiveeﬀectoffenoﬁbrateadministra-
tion in C57BL/6 mice with cerebrovascular stroke [68]. The
authors suggested that PPARα may represent a new pharma-
cological target to reduce the neuroinﬂammatory and neu-
ropathological sequelae of cerebrovascular stroke [68].
In traumatic brain injury, the PPARα agonist fenoﬁ-
brate appears to represent a highly promising new anti-
inﬂammatory compound. Besson et al. assessed the phar-
macological role of fenoﬁbrate in a model of experimental
ﬂuid-percussion injury in adult male Sprague-Dawley rats
[21]. The authors revealed that the administration of fenoﬁ-
brate during a clinically relevant therapeutic “time window
of opportunity” at 1 hour after trauma mediated a signiﬁ-
cant posttraumatic neuroprotection. This was demonstrated
by improved neurological scores in the fenoﬁbrate group
at 24 hours and 7 days after trauma, compared to vehicle-
treated animals [21]. Morphologically, fenoﬁbrate treatment
resulted in signiﬁcantly decreased extent of brain edema at
24 hours after head injury, compared to the placebo group.
The authors furthermore described a marked reduction in
intercellular adhesion molecule (ICAM)-1 expression at the
protein level by immunohistochemistry in injured rat brain4 PPAR Research
sections after fenoﬁbrate administration [21]. This ﬁnding
implies a reduced extent of intracerebral immunoactivation
andneuroinﬂammationinratstreatedbythePPARαagonist,
compared to vehicle controls.
A more recent follow-up study by the same research
group assessed the role of PPARα in modulating the ox-
idative stress in the injured rat brain [17]. Oxidative stress
and ischemia/reperfusion-mediated injuries contribute sig-
niﬁcantly to the extent of posttraumatic intracerebral
inﬂammation and delayed secondary brain damage after
headinjury[13,69,70].Pathophysiologically,contusedbrain
areas are surrounded by a penumbra zone which is hypoper-
fused due to traumatic vascular damage, loss of cerebrovas-
cular autoregulation, and systemic hypotension. After re-
suscitation, the hypoperfused, ischemic brain areas in the
penumbra zone are reperfused, which leads to activation of
the complement cascade and of reactive oxygen intermedi-
ates by activation of the xanthine oxidase [71, 72]. Oxygen-
d e r i v e df r e er a d i c a l ss u c ha sh y d r o x y li o n s ,h y d r o g e np e r -
oxide, and superoxide anion induce lipid peroxidation, cell
membrane disintegration, and delayed neuronal cell death
(see Figure 2). Lipid peroxidation is facilitated in the brain
due to its genuine vulnerability to oxidative stress based on
speciﬁc morphological characteristics, such as a high ratio
of “membrane to cytoplasm” and high levels of polyunsatu-
rated fatty acids in the CNS [70]. In addition to reactive oxy-
gen intermediates, the generation of nitric oxide (NO) by in-
ducible NO synthase (iNOS) up-regulation also occurs after
head injury and adds to the extent of secondary brain dam-
age [73]. Metabolites emerging from the interaction between
superoxideanionandNO,suchasthehighlyreactiveoxidant
peroxynitrite, have been shown to mediate neurotoxicity and
delayed neuronal cell death after traumatic brain injury [74].
The pharmacological administration of the PPARα
agonist fenoﬁbrate after experimental ﬂuid-percussion in-
jury resulted in a signiﬁcant decrease of intracerebral iNOS
expression [17]. This was associated with a decreased neu-
roinﬂammationintheinjuredbrainandanimprovedneuro-
logical recovery after trauma [17]. These important ﬁndings
imply that the attenuation of oxidative stress may represent a
“key”mechanisticaspectofPPAR-mediatedneuroprotection
after head injury. The pleiotropic beneﬁcial eﬀects of PPARs
in the injured brain, however, are far from being elucidated
in detail until present. For example, in contrast to PPARα,
no studies have yet been performed to analyze the eﬀect of
PPARγ inexperimentalmodelsoftraumaticbraininjury(see
Table 1).
Despite increasing insights into the pathophysiological
mechanisms of posttraumatic neuroinﬂammation and neu-
rodegeneration, clinical neuroprotection trials have failed
to provide a beneﬁt of anti-inﬂammatory pharmacologi-
cal strategies with regard to the outcome after head injury
[75, 76]. Cannabinoids have recently evolved as a promis-
ing new therapeutic avenue for neuroprotection after head
injury [77–79]. This group of compounds consists of natu-
ral (endocannabinoids) and synthetic ligands, such as dex-
anabinol (HU-211). The endocannabinoid 2-arachidonoyl
glycerol (2-AG) has received increased attention in recent




















Figure 2: Working hypothesis of PPAR-mediated mechanisms of neu-
roprotection after traumatic brain injury. The neuropathological se-
quelaeofheadinjuryincludetheposttraumaticactivationofNFκB-
dependent inﬂammatory genes. The transcription of neuroinﬂam-
matory mediators in the injured brain induces and perpetuates the
intracranial inﬂammatory response and leads to formation of brain
edema and adverse outcome. Activation of PPARs by binding of
syntheticligands,suchasthePPARαagonistfenoﬁbrate,leadstoin-
hibition of NFκB and of downstream transcribed proinﬂammatory
and proapoptotic mediators. In addition, cannabinoids have a dual
neuroprotective function, (1) by acting as ligands to PPARs and (2)
byinhibiting“key”mediatorsofneuroinﬂammationandapoptosis,
such as tumor necrosis factor (TNF). The combination therapy of
synthetic PPAR agonists and cannabinoids may represent the long
sought pharmacological “golden bullet” for the treatment of trau-
matic brain injury in the future.
jury, by inhibition of proinﬂammatory cytokines, reactive
oxygen intermediates, and excitotoxic aminoacids, such as
glutamate [80, 81]. The pharmacological agent dexanabi-
nol was shown to mediate neuroprotection by inhibition
of TNF production in injured rodent brains [77, 82]a n d
was recently proposed as an eﬀective neuroprotective strat-
egy to reduce the extent of secondary brain injury in hu-
mans (see Figure 2)[ 78, 79]. Dexanabinol (HU-211) is a
nonpsychotropic, synthetic cannabinoid which exerts ben-
eﬁcial eﬀects by cytokine inhibition and radical scaveng-
ing associated with reduction of brain edema [77–79, 82].
Cannabinoids were attributed a new role as neuroprotec-
tive agents by agonistic action to PPARs [83]. The func-
tional interaction between cannabinoids and PPARs was
ﬁrst described based on the ﬁnding of oleylethanolamide
(OEA), a lipid derivate structurally related to anandamide,
as a regulator of feeding behavior in rats through activa-
tion of PPARα [68, 84]. Aside from OEA, which is a low-
aﬃnityagonisttocannabinoidreceptors,othercannabinoids
were recently described as PPAR ligands [83]. As such, Δ9-
tetrahydrocannabinol (THC) was found to activate PPARγ
in human cell lines [85]. Of particular interest for neuro-
protection in traumatic brain injury is the ﬁnding that the
potent endocannabinoid 2-AG [80, 81]h a sb e e nf o u n dt o
suppress the proinﬂammatory cytokine IL-2 through PPARγ
signaling, independent of 2-AG binding to cannabinoid re-Philip F. Stahel et al. 5
ceptors [86]. Future studies will have to determine whether
cannabinoids represent the long sought “golden bullet” for
reduction of secondary brain damage after head injury. It
seems reasonable to suggest that a combination of neuro-
protective cannabinoids, such as dexanabinol, with other
potent anti-inﬂammatory therapeutic agents, such as syn-
thetic PPAR ligands, may represent a promising new thera-
peutic avenue for improving the outcome of traumatic brain
injury.
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